Association between Drug and Vaccine Use and Acute Immune Thrombocytopenia in Childhood A Case-Control Study in Italy

被引:41
作者
Bertuola, Federica [1 ]
Morando, Carla [1 ]
Menniti-Ippolito, Francesca [2 ]
Da Cas, Roberto [2 ]
Capuano, Annalisa [3 ]
Perilongo, Giorgio [1 ]
Da Dalt, Liviana [1 ]
机构
[1] Univ Padua, Dept Pediat, I-35128 Padua, Italy
[2] Natl Ctr Epidemiol Surveillance & Hlth Promot, Natl Inst Hlth, Rome, Italy
[3] Univ Naples 2, Dept Expt Med, Sect Pharmacol L Donatelli, Naples, Italy
关键词
PURPURA; DIAGNOSIS; MEASLES; MUMPS; RISK;
D O I
10.2165/11530350-000000000-00000
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Immune thrombocytopenic purpura (ITP) is an immuno-mediated disease characterized by a decrease in platelet count and, in its more severe forms, by bleeding symptoms. Many drugs have been implicated in the pathogenesis of drug-induced thrombocytopenia in adults; only limited data on drug-related ITP in children have been published. Objective: Our study was set up to evaluate the consistency of the association between drug and vaccine use and ITP in children. Study Design: This study is part of an Italian multicentre study oil adverse drug reactions in children, coordinated by the Italian National Institute of Health, which was started in November 1999 and is ongoing. Patients or Other Participants: The study was conducted by enrolling all children aged more than I month who were hospitalized through the paediatric emergency department for the following conditions: thrombocytopenia (platelet count <100x10(3)/L); acute neurological disorders; non-infectious mucocutaneous diseases and vasculitis; and endoscopically confirmed gastroduodenal lesions and/or clinically defined haematemesis and melaena. Children with chronic pathologies or concomitant diagnoses of cancer or immunodeficiency were not included in our study. Main Outcome Measure: During hospital admission, a physician interviewed parents using a structured questionnaire. The main aim of the interview was to collect information on drug exposure in a time period of 3 weeks and vaccine exposure in a period of 6 weeks preceding hospitalization. Using a case-control study design, exposure of children with thrombocytopenia (cases) to drugs and vaccines was compared with similar exposure of children with gastroduodenal lesions and neurological disorders (controls); this allowed us to estimate the odds ratios (ORs) of the occurrence of thrombocytopenia associated with the use of drugs or vaccines. Results: Up to December 2007, the study population included 387 cases of thrombocytopenia and 1924 controls. Despite the low platelet count, ITP was generally a mild disease, without serious bleeding in the majority of cases and associated with a short length of hospital stay. After adjusting for concurrent use of other drugs, use of the antibacterials was associated with a more than 2-fold increase in the risk of developing ITP (OR 2.4; 95% CI 1.8, 3.1). Mucolytics and NSAIDs were associated with an OR of 1.9; 95% CI 1.2, 2.9 and 1.5; 95% CI 1.0, 2.1 respectively, while paracetamol (acetaminophen) was associated with an OR of 1.5; 95% CI 1.2, 2.0. MMR vaccination was associated with an increased risk of developing ITP (OR 2.4; 95% CI 1.2, 4.7). Conclusions: The results of this study provide evidence for an association between ITP and exposure to selected antibacterials, NSAIDs, paracetamol, mucolytics and MMR vaccination.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 26 条
[1]   Current concepts - Drug-induced immune thrombocytopenia [J].
Aster, Richard H. ;
Bougie, Daniel W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (06) :580-587
[2]   MMR vaccine and idiopathic thrombocytopaenic purpura [J].
Black, C ;
Kaye, JA ;
Jick, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (01) :107-111
[3]   Childhood immune thrombocytopenic purpura: Diagnosis and management [J].
Blanchette, Victor ;
Bolton-Maggs, Paula .
PEDIATRIC CLINICS OF NORTH AMERICA, 2008, 55 (02) :393-+
[4]   Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines [J].
BoltonMaggs, PHB ;
Moon, I .
LANCET, 1997, 350 (9078) :620-623
[5]   Autoimmune thrombocytopenia [J].
Chong, BH ;
Ho, SJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (08) :1763-1772
[6]   The epidemiology of immune thrombocytopenic purpura [J].
Fogarty, Patrick F. ;
Segal, Jodi B. .
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (05) :515-519
[7]   Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children [J].
France, Eric K. ;
Glanz, Jason ;
Xu, Stanley ;
Hambidge, Simon ;
Yamasaki, Kristi ;
Black, Steve B. ;
Marcy, Michael ;
Mullooly, John P. ;
Jackson, Lisa A. ;
Nordin, James ;
Belongia, Edward A. ;
Hohman, K. ;
Chen, Robert T. ;
Davis, Robert .
PEDIATRICS, 2008, 121 (03) :E687-E692
[8]   Risk of clinical blood dyscrasia in a cohort of antibiotic users [J].
Huerta, C ;
Rodríguez, LAG .
PHARMACOTHERAPY, 2002, 22 (05) :630-636
[9]   PREVIOUS MYCOPLASMA-PNEUMONIAE INFECTION CAUSING SEVERE THROMBOCYTOPENIC PURPURA [J].
ISOYAMA, K ;
YAMADA, K .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) :252-253
[10]   Thrombocytopenic purpura after measles, mumps and rubella vaccination: A retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Merieux serums et vaccins [J].
JonvilleBera, AP ;
Autret, E ;
GalyEyraud, C ;
Hessel, L .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (01) :44-48